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Summary 
The purpose of this work is to investigate the link between an altered intestinal mcro-
biota or dysbiosis and chronic inflammatory disorders, in particular inflammatory bowel 
disease (IBD). Along with probiotics, faecal microbiota transplantation (FMT) opts to be 
a promising therapeutic treatment for restoring the bacterial homeostasis of the hu-
man intestine and reducing the risk of colorectal carcinogenesis. Microbiota is the com-
plex microbial flora that resides in the gut establishing a mutually beneficial relation-
ship. Alteration of the microbiota’s composition, termed as dysbiosis, may lead to 
pathological conditions. Treatment with probiotics can restore the normal commensal 
flora in IBD. Intestinal microbiota affects the circadian rhythm which in turn regulates 
the expression of different genes in GALT (gut associated lymphoid tissue) playing a 
role in the prevention of inflammation and colorectal cancer (CRC) progression. This 
article highlights the involvement of different microbial strains in the pathogenesis of 
dysbiosis and in the creation of a carcinogenic milieu caused by an altered stimulation 
of the immune system. Therapies targeting the equilibrium of the microbiota to switch 
off chronic inflammation and prevent the progression to CRC seem to be a promising 
therapeutic tool for a variety of inflammation-associated diseases. 
Introduction 
Microbial involvement in Inflammatory Bowel Diseases (IBDs) and Colon-Rectal Can-
cer (CRC) is nowadays well established. Technological advances allowed assessing a 
considerable amount of data concerning 
possible genetic susceptibility to Crohn’s 
disease rather than Ulcerative Colitis and 
Colon-rectal cancer. The development of 
newer molecular tools for the global as-
sessment of the gut microbiome and the 
identification of nucleotide-binding oli-
gomerization domain-containing protein 
2 (NOD2) in 2001 and other susceptible 
genes for Crohn's disease in particular 
has led to better understanding of the 
aetiopathogenesis of IBDs. The microbial 
studies projected towards a much deeper 
elucidation about normal composition of 
the gut microbiome and its perturbations 
in the setting of IBDs. Condition of 
“altered” microbiome is called "dysbiosis" 
and represents a key player in the pro-
tracted course of inflammation in IBDs 
and, possibly in CRC. Numerous genome-
wide association studies have identified 
further genes involved in gastrointestinal 
innate immunity to better elucidate the 
relationship of the local innate immunity 
with the adjacent luminal bacteria. This 
knowledge has also spurred the search 
for specific pathogens, which may have a 
role in the metamorphosis of the gut mi-
crobiome from a symbiotic entity to a pu-
tative pathogenic one. Here we review 
advances in our understanding of micro-
bial involvement in IBD and CRC patho-
genesis to shape over therapeutic man-
agement of gastro-intestinal diseases in 
the coming years. 
 
Epidemiology and clinical manifesta-
tion of IBD 
IBDs mean the inflammatory bowel dis-
eases with chronic recurring character. 
IBDs are a group of pathologies encom-
passing Crohn’s Disease (CD) and Ulcera-
tive Colitis (UC) with a significantly aug-
mented prevalence and incidence in in-
dustrialized countries [1]. It seems that 
the way of life together with the eating 
habits of the people living in the most 
industrialized countries are more suscep-
tible to the onset of IBDs. Worldwide 
prevalence and incidence of IBDs are 
summarized in Table 1.  
In UC mucosal lesions appear in the rec-
tum and extend to the entire colon with a 
hyperemic mucosa and in severe cases, 
bloody and ulcerated with pseudo-polyps. 
On the other hand, CD can affect any 
part of the gastrointestinal tract from the 
mouth to the anus. These chronic inflam-
matory pathologies involve systemic 
clinical manifestations ranging from or-
thopedics (arthritis) [2], cardiovascular 
(endocarditis) [3], endocrinological 
(thyroiditis) [4], ocular (conjunctivitis, 
episcleritis, scleritis and uveitis) [5], and 
cutaneous 
(pyoderma gangrenosum, acne, 
and suppurative hidradenitis) [6] involve-
ment. 
In patients affected by IBD and secon-
dary arthritis, bacterial antigens and ge-
netic material, often belonging to gram-
negative, have been found in synovial 
fluid.  
Furthermore, several studies have shown 
that aberrant migration of intestinal lym-
phocytes or mononuclear cells is respon-
sible for the onset of joint inflammation 
[7]. This phenomenon is probably due to 
the penetration of saprophytic commen-
sal microflora through damaged tight 
mucosal joints with consequent loss of 
impermeability. Genetic polymorphisms 
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WORLDWIDE PREVALENCE 
Crohn's disease Ulcerative colitis 
26 to 199 cases on 100.000 people 37 to 246 cases on 100.000 people 
201 on 100.000 adults 238 on 100.000 adults 
WORLDWIDE INCIDENCE 
Crohn's disease Ulcerative colitis 
3.1 to 14.6 cases on 100.000 people 2.2 to 14.3 cases on 100.000 people 
Table 1. Data obtained from Center for Disease Control and Prevention website. 
of HLA-B27 and of the receptor for inter-
leukin 23 increase both the risk and sus-
ceptibility of developing both IBD and 
arthritis [8, 9]. Since among the micro-
organisms detectable in CD patients 
there is Klebsiella, infection by this bac-
terium in the bowel may cause ankylos-
ing spondylitis, through the production of 
anti-Klebsiella antibodies. The latter, can 
also bind to cross-reactive self-antigens 
like HLA-B27 and collagen fibers in the 
joints, with a release of further new anti-
gens on the surface of damaged tissue. 
These new antigens are responsible for 
prolonged or continuous production of 
autoantibodies and further damages to 
the articular tissues with a perpetuation 
in the disease process. Recurrent Kleb-
siella infections could explain the charac-
teristic trend present in patients affected 
by CD and ankylosing spondylitis, con-
sisting in remission/exacerbation fea-
tures, observed frequently in patients 
with these diseases [10]. Moreover, in 
serum and colonic biopsies derived from 
IBD patients, elevated levels of Hsp60, 
Hsp10, Hsp70 and Hsp90have been de-
tected. The latter, present molecular 
structures very similar to those detect-
able in the microbiome counterpart, sup-
porting the hypothesis of an exacerbated 
GALT activation in response to these self
-antigens through the phenomenon of 
molecular mimicry at the base of IBD 
etiopathogenesis [11, 12]. 
 
Biological circadian regulation of 
colonocytes gene expression in re-
sponse to microbiota and dysbiosis 
conditions 
The microbial associated molecular pat-
terns (MAMPs) are responsible for the 
activation of immune system through 
interacting with pattern recognition re-
ceptors (PRRs) and subsequent trigger-
ing of inflammatory processes. Recent 
evidences support the great importance 
of sleeping processes to prevent several 
pathological conditions and also inflam-
matory, even CRC [13]. The circadian 
rhythm switches on/off different genes in 
GALT (Gut Associated Lymphoid Tissue), 
among them TLR1, TLR5, TLR9 and 
NOD2. Several homeostatic intestinal 
processes such as nutrient absorption, 
cell proliferation, gut motility and meta-
bolic activities are known to be regulated 
in a circadian manner [14]. Components 
of circadian clock, like BMAL1, are re-
quired for the correct functionality, in 
mouse small intestine, of some TLR 
genes expressed in a circadian manner 
[15]. The gene encoding for NOD2 recep-
tor, which belongs to the group of NLR 
intracellular receptors genes [16], was 
the first susceptible gene to be linked to 
Crohn’s disease. Moreover, NLR is impor-
tant for the release of antibacterial com-
pounds, like Cryptidins by Paneth cells; 
for this reason microbiota-depleted mice 
show a major intestinal susceptibility to 
inflammation and colitis [17]. Thus, it is 
very important to highlight that the dia-
logue between PRRs expression and bac-
terial MAMPs is highly regulated. The ab-
sence of microbiota precludes PRR-
mediated signaling, as well as the func-
tion of the clock, thus impairing genic 
expression in colocytes, dependent on 
both PRRs and clock components, repre-
senting the base for the breakage of the 
delicate equilibrium involved in regulation 
of gut innate and adaptive immunity. 
Furthermore, the expression of several 
genes involved in gut innate immunity 
(Angiogenin 4, TSLP, and Claudin2 and 
Claudin12) is microbiota-vitamin D3 de-
pendent, since a defective vitamin D3 
receptor signaling has been shown to in-
crease the susceptibility to IBD [18]. 
RORα transcription factor seems to be 
involved in the circadian activation of 
Bmal1 expression in colonic nuocytes 
[19]. Moreover, short chain fatty acid re-
ceptor FFAR3 (GPR41), involved in intes-
tinal motility control [20], appears to be 
regulated by RORα in a ZT0 > ZT12 cir-
cadian manner. In fact, in antibiotic-
induced microbiota-depleted mice, FFAR3 
is significantly decreased. Of note, rhyth-
mic activation of IKKb and JNK repre-
sents a very important factor for correct 
timing of colocytes homeostatic functions 
dependent on genes activated by AP1 
and NF-kB, showing a circadian activation 
pattern at diurnal times ZT20- ZT4 which 
correspond to the mouse ‘‘active phase’’. 
Furthermore, the circadian rhythm of 
IKKb and JNK activation prevents the in-
appropriate activation of RevErba by 
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PPARα. Together these mechanisms en-
sure that, during the same ZT20-ZT4 ac-
tive phase, the transactivating (RORα 
and Bmal1/Clock) and transrepressing 
(RevErba/E4BP4) molecular clock compo-
nents can adequately control the tempo-
ral expression of RORE- and E-box-
containing genes encoding colonic ho-
meostatic functions. Importantly, micro-
biota derived MAMPs maintain the cir-
cadian clock through activation of Re-
vErba by PPARα, and also controlling 
proper repression mediated by E4BP4, 
thereby allowing, at diurnal times ZT8– 
ZT16 (rest phase) [21], the expression of 
the numerous D-box-containing genes 
encoding intestinal epithelial cells homeo-
static functions [22]. These conclusions 
suggest that the dialogue between micro-
biota and the circadian system may have 
different effects on the development of 
IBD. 
 
Complementary treatment of 
IBDwith probiotics 
Nowadays, it is well established that in-
flammatory pathologies affecting gastro-
intestinal tract are narrowly correlated to 
dysmicrobism and other various factors 
such as genetic background and diet. 
Since now it is well established that dys-
biosis is a characterizing condition of 
IBD, a question remains to be answered: 
Is dysbiosis a cause of IBD or just a sec-
ondary phenomenon? Research on IBD 
onset and development is oriented to-
wards the investigation of the molecular 
mechanisms underlying the instauration 
and the perpetuation of GALT activation. 
Increasing evidences suggest that the 
intestinal microbiota play a role in initiat-
ing, maintaining, and determining the 
severity of IBD. The precise role of the 
microbiota in the etiology consists in con-
tinuous antigenic stimulation that has the 
potential to activate pathogenic T cells 
and, subsequently, cause chronic intesti-
nal injury. Together, the above men-
tioned factors concur to the typical al-
terations of GALT, characterized in IBDs 
[23]. Mutations in genes encoding for 
PRRs, such as Nod2/CARD15, signifi-
cantly contribute to loss of immune toler-
ance [24,25]. Children with altered mi-
crobial flora have a higher incidence of 
developing IBD during adulthood. Ap-
proaches based on mucosal bacterial iso-
lation show increased concentrations of 
Bacteroides vulgatus and Enterobacteri-
aceae, especially E coli and decreased 
concentrations of Bifidobacteria species, 
in subjects affected by CD [26, 27]. Mu-
cosal specimens derived from CD pa-
tients revealed a highly significant pres-
ence of Mycobacterium avium, suggest-
ing a potential role of this enteric patho-
gen in disease causation [28]. Dysbiosis 
involves the decrease in microbiome bio-
diversity, with underrepresentation of the 
phyla Bacteroidetes and Firmicutes in fe-
ces/mucosa-associated among IBD pa-
tients [29]. In truth, a differentiated ap-
proach should be used in the study of 
microbiome since, there is a difference 
between fecal and mucosa adherent bac-
teria. Indeed, Swidsinski group demon-
strated thick layers of adherent mucosal 
associated bacteria in both UC and CD 
patients with higher bacterial concentra-
tions in CD [30]. Immunological studies 
conducted on patients with IBD revealed 
the presence of specific antibodies and T 
cell subsets in both serum and tissue. In 
particular, significantly higher systemic 
antibody responses were found in UC to-
wards Peptostreptococcus anaerobius, in 
parallel with higher recovery rates of this 
strain from the colonic mucosa [26]. The 
employment of lactic acid-producing or-
ganisms, firstly discovered in the begin-
ning of the 20th century by Metchnikoff, 
revealed a successful tool for ameliorat-
ing inflammatory background [31]. In-
deed, fermented milk contains specific 
compounds and microorganisms, known 
as probiotics, beneficial to human health. 
Probiotics counteract the activation of Nf-
κB, maintaining it bound to IκB in the 
cytoplasm, thus inhibiting pro-
inflammatory cytokines production. 
Hegazy group investigated the effect of 
Lactobacillus delbruekii and Lactobacillus 
fermentum administration on thirty pa-
tients with mild to moderate UC, and 
evaluated their potential immune-
modulating effects. Results derived from 
this study revealed that 8 weeks of ad-
ministration significantly ameliorated the 
inflammation by decreasing the colonic 
concentration of IL-6, expression of TNF-
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α and NF-kB p65, leukocyte recruitment, 
as demonstrated by a decrease in colonic 
MPO activity, and the level of fecal cal-
protectin compared to sulfasalazine 
group and the control [32].Moreover, 
Lactobacillus plantarum has been shown 
to inhibit the degradation of IκB and, 
consequently, the activity of NF-κB in 
vitro [33]. Decreased amount of Faecali-
bacterium prausnitzii have been shown 
to predict high risk for early reactivation 
of ileal Crohn's disease [34]. Probiotic 
based approaches based on the admini-
stration of Lactobacilli and Bifidobacteria 
probiotics have been shown to improve 
clinical symptoms of IBDs through GALT 
immune modulation. In particular, the 
beneficial effects of probiotics have been 
observed in the activation of Treg cells 
through an immunoregulatory response 
involving IL-10 and TGF-β [35]. The 
study of T cell subsets in IBD patients 
indicated a predominance of T helper 17 
cells (Th17). Precisely, IL-17A and IL-
17F are abundantly found in inflamed 
IBD mucosa, suggesting their pivotal role 
in IBD [36].Interestingly, a subpopula-
tion of Th17 (supTh17) cells exhibits im-
mune suppressive properties because it 
expresses high levels of both CD39 and 
FOXP3 and consequently produces ex-
tracellular adenosine. Longhi group re-
ported reduced levels of the above men-
tioned lymphocyte population in IBD pa-
tients [37]. 
Administration of Lactobacillus casei and 
Bifidobacterium lactis in mice with TNBS 
induced colitis led to a significant reduc-
tion of inflammation in the colonic mu-
cosa, reversing malignant changes and 
exerting a potential role in cancer pre-
vention. Benefic effect of probiotic treat-
ment has been observed in the restora-
tion of the goblet cells number back to 
normal. Some of the diverse mechanisms 
of action consist in competing with other 
luminal bacteria, preventing them from 
reaching the lamina propria. Moreover 
probiotics modulate expression of genes 
encoding junction proteins in colocytes to 
ameliorate the epithelial layer structure 
of intestinal mucosa and stimulate the 
mucosal immune system in the patient's 
intestinal tract to secrete protective im-
munoglobulins as secretory IgA and pro-
tective defensins and bacteriocidins in 
the colonic lumen [38]. 
 
Microbiota transplantation for IBD 
treatment: state of the art 
Nowadays, the role of the gastrointestinal 
microbiota in driving chronic inflamma-
tion in IBD is well established, thus treat-
ments based on microbiota manipulation 
resulted of great interest in clinical prac-
tice, with variable evidence for their effi-
cacy. So, an additional alternative treat-
ment for IBD management is represented 
by faecal microbiota transplantation 
(FMT). The principal of FMT for this indi-
cation is predicated on the concept that 
antibiotic therapy disrupts the normal 
microbial homeostasis, allowing pathogen 
colonization. FMT rational consists of the 
transfer of gastrointestinal microbiota 
from a healthy donor to IBD patient by 
duodenal infusion of liquid stool suspen-
sion. In rodent models, FMT offers both 
an investigational tool to study the role of 
microbes in disease development and 
treatment response, as well as a new 
therapeutic intervention. The gained 
credibility in the clinical world on FMT is 
subsequent to the first publication on the 
effectiveness of this treatment for antibi-
otic-resistant C difficile–induced diarrhea 
[39]. Re-establishment of microbial ho-
meostasis has been demonstrated by sig-
nificant increase in Bacteroidetes species 
and Clostridium species clusters IV and 
XIVa and a decrease in Proteobacteria, 
according to healthy donor profiles. Re-
cently, Suskind DL group enrolled nine 
patients, aged 12 to 19 years with mild-
to-moderate Crohn’s disease, to undergo 
FMT by nasogastric tube opting for reduc-
ing the intestinal inflammation by alter-
ing the fecal dysbiosis. Follow-up evalua-
tions at 2, 6, and 12 weeks, considering 
PCDAI parameters, showed an improve-
ment in mean PCDAI score at 2 weeks to 
6.4 ± 6.6 and at 6 weeks to 8.6 ± 4.9. 
Results revealed a late remission in pa-
tients who did not receive any treatment 
of engraftment [40]. FMT therapeutic ap-
proaches used for IBD treatment are re-
ported in Table 2.  
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Microbiota, dysbiosis and coloncan-
cer 
Studies conducted on initiation and pro-
motion of colon-rectal carcinogenesis re-
vealed the crucial role of the rupture in 
the physiological equilibrium between the 
commensal bacteria inhabiting colonic 
mucosa. Indeed, some bacterial strains 
may “drive” initial pathological changes 
in colocytes behavior and immune sys-
tem responses. Physiologically, the mutu-
alistic relationships between commensal 
bacteria and epithelium, promote colonic 
health counteracting meanwhile patho-
gen infections, opposing the creation of 
favorable conditions for developing CRC. 
Although >80% of intestinal bacteria 
cannot be cultured, identification of all 
bacteria has become possible by using 
high technology to perform whole DNA 
genome sequencing. With the evolve-
ment of phylogenetic analysis of bacterial 
16 S rRNA genes this goal has been 
achieved. In fact, Firmicutes, Bacteroide-
tes, and Proteobacteria were reported as 
the most dominant phyla in bacteria ad-
herent to precancerous adenomatous 
polyps [49]. 
Thus, once mucosal integrity is de-
stroyed, other bacteria can pass in the 
injured zone and support CRC develop-
ment. The creation of a carcinogenic en-
vironment may be caused by a decrease 
in levels of butyrate-producing species 
such as Ruminococcus and Roseburia 
species relative to controls [50].The 
gram-negative bacteriumFusobacterium 
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  Outcome Author 
Mild to moderate 
Crohn’s disease 
7 of 9 patients in remission 
at 2 weeks and 5 of 9 in 
remission at 6 and 12 
weeks without additional 
therapies 
[40] Suskind DL et al 2015 
IBD patient with two 
Clostridium Difficile 
infections in 18 months 
Microbiota remodeling to-
wards the donor's sample 
composition coinciding with 
symptom resolution at 18 
months follow up 
[41] Brace C et al. 2014 
Crohn’s disease 
CD related improvement 
was not reported 
[42] Grehan et al. 2010 
Crohn’s disease com-
bined with Clostridium 
Difficile infection 
Two cases accepted the 
second FMT due to CDI re-
currence, but the efficacy 
of FMT on CD was not re-
ported 
[43] Hamilton et al. 2012 
Crohn’s disease 
Documented clinical remis-
sion for more than 9 
months 
[44]Zhang et al. 2013 
Ulcerative colitis com-
bined with Clostridium 
difficile infection 
UC relapse 9 days after 
FMT 
[45] De Leon et al. 2013 
Ulcerative colitis com-
bined with Clostridium 
difficile infection 
Diarrhea improved or re-
solved 3 mo after FMT 
[46] Patel et al. 2013 
Ulcerative colitis 
Documented improvement 
from 1 to 36 months 
[47] Borody et al. 2012 
Ulcerative colitis Documented improvement [48] Kump et al. 2013 
Table 2. Therapeutic approaches for IBD treatment 
nucleatum binds to E-cadherin through 
its membrane protein FadA, activating β-
catenin signaling, triggering inflamma-
tory and oncogenic responses [51]. 
Moreover, high levels of Fusobacterium 
nucleatumresult prevalent in stool de-
rived from subjects affected by CRC, 
suggesting a potential role of this micror-
ganism in initiation and progression 
processes [52]. Increased levels of Ak-
kermansia muciniphila and Citrobacter 
farmer have been reported in CRC cases 
and, depletion of the first mentioned 
strain, results associated with IBD devel-
opment. On the other hand, depletion of 
Bifidobacterium longan, Clostridium clos-
tridioforme, and Ruminococcus species 
have been reported in CRC cases [50]. 
Thus, bacterial metabolites evoke an im-
mune response characterized by in-
creased levels of IL-17, supporting can-
cer progression [53]. On the other hand, 
innate immunity activated by bacterial 
PAMPs, has been reported as a very im-
portant factor for tumor progression in 
murine models. Indeed TLR2 and TLR4, 
play a crucial role in tumor formation, 
especially in presence of specific human 
genetic polymorphisms such as TLR4 
299Gly [54]. In colitis-associated CCR, 
TLR signaling activates Epiregulin, re-
sponsible of ERK activation and then, ac-
tively supporting tumor growth [55]. 
Studies conducted on murine models, 
reveal that dysbiosis “alone” is able to 
induce CCR formation in presence of 
polymorphisms responsible of reduced 
activity of NOD2 [56]. Molecular dynam-
ics at the base of dysbiosis induced CCR 
encompass production of genotoxic me-
tabolites from different bacterial strains 
such as Escherichia coli, Enterococcus 
faecalis, and B.fragilis. In particular, cyc-
lomodulins produced by groups B2 and D 
of Escherichia Coli, exert detrimental ef-
fects in the mechanisms responsible of 
cellular differentiation, apoptosis, and 
proliferation control [57]. A direct dam-
age of DNA integrity is caused by 
B.fragilis toxin, in particular through a 
mechanism involving the polyamine ca-
tabolism [58]. Sobhani group reported 
significantly increase of bacteria belong-
ing to Bacteroides/Prevotella group in 
CRC patients, compared to healthy inde-
pendently from age and BMI [59]. The 
great importance of colonic microbiome 
in CRC development is substantiated by 
experiments of stool transfer from indi-
viduals with colon cancer and healthy 
germ-free mice. Follow up to 6 weeks 
revealed that composition of microbiota 
in mice’s stools was of human type and 
remained stable over time. However, cell 
proliferation and aberrant crypt foci in-
creased in the colons of mice given the 
cancerous stools [60]. Regular probiotics 
intake may actively prevent the initiation 
and development of CRC. In fact, 
Hatakka group reported a significant low-
ering in putative pro-carcinogenic enzy-
matic activities such as β-glucosidase, β-
glucuronidase and urease after Lactoba-
cillus Rhamnosus administration [61]. 
Recently, it has been tested on HT-29 
(colon tumor cell line) a particular bacte-
rial strain derived from vaginal secretions 
of adolescent and young adult women, 
belonging to the Lactobacillus plantarum 
species. The isolated strain, exhibited 
probiotic properties such as low pH and 
antimicrobial activity against some 
pathogenic bacteria. Moreover, Lactoba-
cillus plantarum 5BL strain exhibited de-
sirable remarkable anticancer activity 
against the tested human cancer cell line 
showing favorable potential as a bioac-
tive therapeutic agent [62, 63].  
 
Conclusions 
Ulterior clinical investigations on the mu-
tualistic relationship microbiota-colonic 
mucosa are useful to clarify the physio-
logical, biochemical and immunoregula-
tory dynamics. Treatment of IBDs with 
probiotic based therapies may signifi-
cantly improve life quality and reduce 
risk of progression towards the onset of 
CRC. It results very interesting the dis-
covery of supTh17 since, until now, T 
lymphocytes producing IL17 have been 
usually addicted as detrimental for the 
immune homeostasis in colonic mucosa. 
Therapies oriented towards the equilib-
rium of microbial may represent the key 
strategy to switch off chronic inflamma-
tory processes hitting colonic mucosa 
preventing at the same time the onset of 
CRC. Data reported in this review could 
prompt research on IBD and CRC to 
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deepen the knowledge about microbiota, 
not intended exclusively as colonic, and 
to discover potential biological weapon 
useful to both switch off chronic inflam-
mation and actively prevent carcinogene-
sis. 
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